Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 160)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 19.01.24 22:21:17 von
neuester Beitrag 19.01.24 22:21:17 von
Beiträge: 2.935
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 1
Gesamt: 345.743
Gesamt: 345.743
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: RXK3
1,2760
EUR
+1,75 %
+0,0220 EUR
Letzter Kurs 13:06:47 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 13,110 | +38,44 | |
| 6,5000 | +27,45 | |
| 0,6300 | +26,28 | |
| 1,0580 | +22,03 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,8500 | -14,45 | |
| 0,9378 | -18,55 | |
| 36,70 | -22,87 | |
| 2,3450 | -25,32 | |
| 15,600 | -31,64 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 50.188.833 von Turnover15 am 15.07.15 07:42:55Moin Turnover,
da hast'd Recht, bärenstark gestern stateside, ich rieche einen "fetten Ausbruch" im baldigen Anmarsch....
da hast'd Recht, bärenstark gestern stateside, ich rieche einen "fetten Ausbruch" im baldigen Anmarsch....
Starker Schlussspurt gestern
AH 1.85 Up 0.15(8.82%)
AH 1.85 Up 0.15(8.82%)
Antwort auf Beitrag Nr.: 50.176.653 von kwhistler am 13.07.15 17:04:10Sehr schön kwhistler....dieses passt nahtlos dazu (Der FDA wird demnächst auch unter zugzwang stehen- und wir befinden uns fett mitten im Phase 3 trials ...das passt!
The Accelerated Approval Debate
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411233/
US biotechs werden so gaaaannnzzz langsam "sexy"....
The Accelerated Approval Debate
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411233/
US biotechs werden so gaaaannnzzz langsam "sexy"....
Antwort auf Beitrag Nr.: 50.175.438 von Growth2012 am 13.07.15 15:03:35
Ja sehr gute Aussichten!!
...und wenn es dann mit der FDA noch schneller geht - na dann aber!!!
US House Of Representatives Passes Accelerated Drug Approval Process - Senate Next
Davis Votes to Modernize Our Health Care Infrastructure, Accelerate Approval Process for New Cures
Washington, Jul 10
U.S. Rep. Rodney Davis (R-Ill.) today released the following statement after the House overwhelmingly passed H.R. 6, the 21st Century Cures Act, by a vote of 344-77. Davis was an early cosponsor of this bipartisan bill to modernize our health care infrastructure and accelerate the approval process for new drug development, medical devices, and other treatments.
“Today, it takes an average of 15 years to move a drug from the lab to our local pharmacies,” said Davis. “And like too many of my constituents, my family has been impacted by illness, both successful and unsuccessful battles with cancer, so if we can speed up this process by even just one year by cutting through bureaucratic red tape, we must do so. I came to Congress to make Washington work for the people I serve and today I’m proud the House took the lead on a bipartisan bill that could save millions and help so many others live longer, healthier lives.”
The 21st Century Cures Act makes the following improvements to our innovative health care infrastructure:
• Removes regulatory uncertainty for the development of new medical apps;
• Modernizes clinical trials;
• Provides incentives for developing drugs to fight rare diseases;
• Removes barriers to improving and increasing research capabilities;
• Improving coordination with the entire biomedical system to find cures more quickly;
• Makes investments in 21st century science; and
• Implements long-term reforms that will reduce the deficit by $500 million over the next 10 years and an additional $7 billion the following decade.
Ja sehr gute Aussichten!!
...und wenn es dann mit der FDA noch schneller geht - na dann aber!!!
US House Of Representatives Passes Accelerated Drug Approval Process - Senate Next
Davis Votes to Modernize Our Health Care Infrastructure, Accelerate Approval Process for New Cures
Washington, Jul 10
U.S. Rep. Rodney Davis (R-Ill.) today released the following statement after the House overwhelmingly passed H.R. 6, the 21st Century Cures Act, by a vote of 344-77. Davis was an early cosponsor of this bipartisan bill to modernize our health care infrastructure and accelerate the approval process for new drug development, medical devices, and other treatments.
“Today, it takes an average of 15 years to move a drug from the lab to our local pharmacies,” said Davis. “And like too many of my constituents, my family has been impacted by illness, both successful and unsuccessful battles with cancer, so if we can speed up this process by even just one year by cutting through bureaucratic red tape, we must do so. I came to Congress to make Washington work for the people I serve and today I’m proud the House took the lead on a bipartisan bill that could save millions and help so many others live longer, healthier lives.”
The 21st Century Cures Act makes the following improvements to our innovative health care infrastructure:
• Removes regulatory uncertainty for the development of new medical apps;
• Modernizes clinical trials;
• Provides incentives for developing drugs to fight rare diseases;
• Removes barriers to improving and increasing research capabilities;
• Improving coordination with the entire biomedical system to find cures more quickly;
• Makes investments in 21st century science; and
• Implements long-term reforms that will reduce the deficit by $500 million over the next 10 years and an additional $7 billion the following decade.
Endlich mal ein Yahoo Posting der die "Copy Paste" Einsatz würdig ist...
The true values of Gale
.
(1) Existing product lines include Abstal and Zuplenz.
(2) Product line on waiting: Gale-401 (Anagreline CR)
(3) NeuVax Phase 3 clinical trial (PRESENT) with SPA
(4) NeuVax + Herceptin Phase 2b HER2 1+ and 2+. Phase 2a yielded 0% of breast cancer recurrence. This is carried out with support from Genetech/Roche.
(5) NeuVax + Herceptin Phase 2 HER2 3+. this trial was awarded through the Congressionally Directed Medical Research Program (CDMRP), funded through the Department of Defense (DoD).
(6) Gale-301 Phase 2 trial is an adjuvant treatment to prevent recurrences in high-risk ovarian cancer patients. It has been reported that this Folate Binding Protein has the ability to prevent 78% of ovarian cancer from recurring.
(7) Partnership with Teva to conduct NeuVax clinical trials in Israel and to market NeuVax in Israel and surrounding regions if NeuVax is found effective in preventing breast cancer from recurring.
(8) Partnership with Leica to use its best breast cancer imaging system to select the best candidate for NeuVax Phase 3 trials.
(9) Partnership with Dr. Reddy to conduct NeuVax Phase 2 clinical trial on gastric cancer patient in India.
(10) Gale has $50 million cash on hand and a further access to $50 million from Lincoln Parks to finance its operations.
These 10 powerful values should render much confidence to Gale investors.
http://finance.yahoo.com/mbview/threadview/?&bn=12a6b315-348…
The true values of Gale
.
(1) Existing product lines include Abstal and Zuplenz.
(2) Product line on waiting: Gale-401 (Anagreline CR)
(3) NeuVax Phase 3 clinical trial (PRESENT) with SPA
(4) NeuVax + Herceptin Phase 2b HER2 1+ and 2+. Phase 2a yielded 0% of breast cancer recurrence. This is carried out with support from Genetech/Roche.
(5) NeuVax + Herceptin Phase 2 HER2 3+. this trial was awarded through the Congressionally Directed Medical Research Program (CDMRP), funded through the Department of Defense (DoD).
(6) Gale-301 Phase 2 trial is an adjuvant treatment to prevent recurrences in high-risk ovarian cancer patients. It has been reported that this Folate Binding Protein has the ability to prevent 78% of ovarian cancer from recurring.
(7) Partnership with Teva to conduct NeuVax clinical trials in Israel and to market NeuVax in Israel and surrounding regions if NeuVax is found effective in preventing breast cancer from recurring.
(8) Partnership with Leica to use its best breast cancer imaging system to select the best candidate for NeuVax Phase 3 trials.
(9) Partnership with Dr. Reddy to conduct NeuVax Phase 2 clinical trial on gastric cancer patient in India.
(10) Gale has $50 million cash on hand and a further access to $50 million from Lincoln Parks to finance its operations.
These 10 powerful values should render much confidence to Gale investors.
http://finance.yahoo.com/mbview/threadview/?&bn=12a6b315-348…
Trading Spotlight
...war'n 'strong run & close' am Freitag, hoffe auf ein starken "rebound modus" ab nächster Woche (sprich ab morgen um die 15:30
)
Antwort auf Beitrag Nr.: 50.161.980 von patg am 10.07.15 19:51:16Das ist schon richtig aber die Top-Line Data of GALE 301 stehen noch aus. Stehen im FDA Kalender mit 30.06.2015 verzeichnet.
Hier die Info dazu:
Presented GALE-301 Phase 2a clinical trial data at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting. The Phase 1/2a trial enrolled 51 patients and preliminary data demonstrated that GALE-301 is well tolerated and elicits a strong in vivo immune response with primarily Grade 1 and Grade 2 toxicities. The data showed a 31% recurrence rate in the vaccine group compared to 50% in the control group at a median follow up of 13 months, a 38% reduction in relative risk of recurrence. Galena expects the top-line data to be presented mid-year 2015.
http://investors.galenabiopharma.com/releasedetail.cfm?Relea…
Würden dem Kurs aktuell sicher noch einmal gut tun wenn positiv...
Hier die Info dazu:
Presented GALE-301 Phase 2a clinical trial data at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting. The Phase 1/2a trial enrolled 51 patients and preliminary data demonstrated that GALE-301 is well tolerated and elicits a strong in vivo immune response with primarily Grade 1 and Grade 2 toxicities. The data showed a 31% recurrence rate in the vaccine group compared to 50% in the control group at a median follow up of 13 months, a 38% reduction in relative risk of recurrence. Galena expects the top-line data to be presented mid-year 2015.
http://investors.galenabiopharma.com/releasedetail.cfm?Relea…
Würden dem Kurs aktuell sicher noch einmal gut tun wenn positiv...
Antwort auf Beitrag Nr.: 50.160.042 von DerGierige am 10.07.15 15:58:25Phase 2 und 2a
wurde bereits veröffentlicht....
http://seekingalpha.com/news/2580385-galenas-anagrelide-show…
wurde bereits veröffentlicht....
http://seekingalpha.com/news/2580385-galenas-anagrelide-show…
Der 30.6.2015 ist vorbei,sollten da nicht ein paar wichtige Zwischenergebnisse kommen?
manche reden auch von einer gesunden Korrektur!
Durchsuchen
